Aprotinin

Phase 3Small molecule

Bayer

Aprotinin is one of 117 small molecule programs targeting Pancreatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

PancreatitisActive, not recruiting

Breast CancerActive, not recruiting

COVID-19Active, not recruiting

Acute Respiratory Distress SyndromeActive, not recruiting

PancreatitisPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Acute Respiratory Distress SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Aprotinin

Bayer

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 3Not yet recruiting

Acute Respiratory Distress Syndrome

NCT07317050

Clinical

Trials by Indication[1]

Cardiopulmonary Bypass1 trial

Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass

Completed·IImperial College London·N/A·NCT00131040·24 enrolled

Breast Cancer1 trial

Phase I Study of Aprotinin in Advanced Breast Cancer

Terminated·—·Phase 1·NCT00354900·18 enrolled

Pancreatitis1 trial

Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery

Completed·NNemours Children's Clinic·Phase 1·NCT00357851·120 enrolled

ESS1 trial

Aprotinin US Special Access Protocol

No longer available· Bayer logo

Bayer··NCT00611845

Acute Respiratory Distress Syndrome1 trial

Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment

Not yet recruiting·FFundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion·Phase 3·NCT07317050·156 enrolled

2 more indications

COVID-191 trial

An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19

Unknown status·AAviron LLC·N/A·NCT04527133·30 enrolled

Cardiac Surgery1 trial

Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates

Completed·SState University of New York - Upstate Medical University··NCT00617955·462 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Aprotinin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aprotinin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aprotinin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Aprotinin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Cardiopulmonary Bypass1 trial

Breast Cancer1 trial

Pancreatitis1 trial

ESS1 trial

Acute Respiratory Distress Syndrome1 trial

COVID-191 trial

Cardiac Surgery1 trial

References

Drug Info

Quick Facts

Related News